Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Clin Cancer Res. 2020 Dec 8;27(5):1305–1315. doi: 10.1158/1078-0432.CCR-20-3310

Figure 4:

Figure 4:

[89Zr]DFO-YS5 targeting specificity in subcutaneous tumor models. A) Maximum intensity projections and μPET/CT of [89Zr]DFO-YS5, [89Zr]DFO-IgG and blocking YS5+[89Zr]DFO-YS5 in DU145 subcutaneous xenograft tumor mice at 48 h. B) Biodistribution of [89Zr]DFO-YS5, [89Zr]DFO-IgG and YS5+[89Zr]DFO-YS5 in DU145 subcutaneous xenograft tumor mice at 48 h. C) Maximum intensity projections and μPET/CT of [89Zr]DFO-YS5 in male nu/nu mice with subcutaneous DU145 and MC38 xenograft at 96 h. D) Biodistribution of [89Zr]DFO-YS5 in male nu/nu mice with subcutaneous DU145 and MC38 xenograft at 96 h.